Ophthalmology in China

Previous Articles     Next Articles

Clinical efficacy comparation of intravitreal injection of ranibizumab and macular photocoagulation for macular edema secondary to non-ischemic retinal branch vein occlusion

Yuan Yu, Wang Jingjing   

  1. Department of Ophthalmology, Hanzhong Central Hospital, Hanzhong 723000, Shaanxi Province, China
  • Received:2019-05-18 Online:2020-05-25 Published:2020-06-05
  • Contact: Wang Jingjing, Email: target029@163.com E-mail:target029@163.com

Abstract: Objective To compare the clinical efficacy and safety of intravitreal injection of ranibizumab and macular photocoagulation in the treatment of macular edema secondary to non-ischemic retinal vein occlusion (BRVO). Design Retrospective comparative case series. Participants 68 patients (68 eyes) who were clinically diagnosed as non-ischemic BRVO secondary macular edema in Hanzhong Central Hospital from June 2015 to June 2018. Methods A total 68 patients (68 eyes) were divided into control group and observation group, 34 cases (34 eyes) in each group. The control group was treated with standard macular grid photocoagulation, while the observation group received intravitreal ranibizumab as needed. LogMAR best corrected visual acuity (BCVA) and central macular thickness (CMT) and adverse events in the two groups were reviewed and compared before and 1, 2, 3, and 6 months after the treatment. Main Outcome Measures BCVA, CMT and adverse events. Results There was no significant differences in LogMAR BCVA and CME between the two groups before treatment ( all P>0.05). Compared with pre-treatment, LogMAR BCVA decreased significantly at 1, 2, 3, and 6 months after treatment in two groups (all P<0.05); the LogMAR BCVA was significantly lower in the observation group than in the control group at 1, 2, 3, and 6 months after treatment (t=3.320, 4.412, 5.580, 5.859, all P<0.05). There were statistically significant differences in CMT between the two groups after treatment (F=5.603, 5.122, all P<0.05), and with the prolongation of time, the CMT of the two groups decreased significantly. The decrease in the observation group was significantly more than that in the control group (t=-8.358, -11.599, -7.792, -4.889, all P<0.05). There were no serious adverse events in both groups. There was no significant difference in the incidence of intraocular and non-intraocular adverse events between the two groups (χ2=1.063, 0.216, both P>0.05). Conclusion The effecicay of ranibizumab in improving the visual acuity and reducing the degree of macular edema of patients with non-ischemic BRVO is significantly better than that of traditional macular grid photocoagulation, and the safety is good.

Key words: branch retina vein occlusion, macular edema, ranibizumab/intravitreal injection, photocoagulation